"Natalizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE.
| Descriptor ID |
D000069442
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.813 D12.776.124.790.651.114.224.060.813 D12.776.377.715.548.114.224.200.813
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Natalizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Natalizumab [D12.776.124.486.485.114.224.060.813]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Natalizumab [D12.776.124.790.651.114.224.060.813]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Natalizumab [D12.776.377.715.548.114.224.200.813]
Below are MeSH descriptors whose meaning is more specific than "Natalizumab".
This graph shows the total number of publications written about "Natalizumab" by people in this website by year, and whether "Natalizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Natalizumab" by people in Profiles.
-
Can Immune Checkpoint Inhibitors Keep JC Virus in Check? N Engl J Med. 2019 04 25; 380(17):1667-1668.
-
Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931.
-
Recurrence of progressive multifocal leukoencephalopathy despite immune recovery in two HIV seropositive individuals. J Neurovirol. 2016 08; 22(4):541-5.
-
JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene. Neurology. 2014 Aug 19; 83(8):727-32.
-
JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol. 2014 Jun; 75(6):925-34.
-
Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study. J Neuropathol Exp Neurol. 2013 Nov; 72(11):1043-51.
-
Gone over to the dark side: Natalizumab-associated JC virus infection of neurons in cerebellar gray matter. Ann Neurol. 2013 Oct; 74(4):503-5.
-
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology. 2012 May 01; 78(18):1390-3.
-
Discrepant findings in immune responses to JC virus in patients receiving natalizumab. Lancet Neurol. 2010 Jun; 9(6):565-6; author reply 566-7.
-
Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med. 2009 Sep 10; 361(11):1067-74.